Center for Cancer Immun Therapy

Center for Cancer Immune Therapy (CCIT)
The aim of CCIT is to improve our ability to bridge the gap between discovery and clinical implementation in the field of cancer immunotherapy. CCIT has a focus on development of immunological treatment of cancer, and has a research profile based on equally weighted experimental and clinical projects facilitating quick clinical implementation of new immunotherapies e.g. anti-CTLA4. It is the European leading centre for use of tumour infiltrating lymphocytes (TIL) for adoptive T-cell therapy (ACT) for metastatic melanoma. CCIT provides the infrastructure of certified clinical grade laboratory for preparation of therapeutic cellular products and evaluations of immune responses.

The laboratory has extensive experience in production of both T-cells and DCs (including mRNA transfection) for clinical use. We also perform characterization of tumour antigens recognized by T cells, studies of T cell and dendritic cell (DC) biology and interactions, and biological monitoring of immune therapies of cancer, e.g. vaccination/DC trials and ACT.

CCIT - homepage